In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

Gary A. Noskin*, Farida Siddiqui, Valentina Stosor, Donna Hacek, Lance R. Peterson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

140 Scopus citations

Abstract

The emergence of resistance in gram-positive bacteria has necessitated a search for new antimicrobial agents. Linezolid is an oxazolidinone, a new class of antibacterial agents with enhanced activity against pathogens. We compared the activity of linezolid to those of other antimicrobial agents against 3,945 clinical isolates. Linezolid demonstrated potent activity against all isolates tested. For all vancomycin-susceptible enterococci, staphylococci, and streptococci, the activity of linezolid was comparable to that of vancomycin. Against oxacillin-resistant staphylococci and vancomycin- resistant enterococci, linezolid was the most active agent tested. In summary, linezolid appears to be a promising new antimicrobial agent for the treatment of gram-positive infections.

Original languageEnglish (US)
Pages (from-to)2059-2062
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume43
Issue number8
DOIs
StatePublished - Aug 1999

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci'. Together they form a unique fingerprint.

Cite this